Purple Biotech to host KOL event on interim results from Phase 2 CM24 study

Purple Biotech announced further details on its virtual key opinion leader event on Thursday, July 11, 2024 at 10:30 AM ET. The event will feature Michael Cecchini, MD and E. Gabriela Chiorean, MD, FASCO, who will discuss the positive interim data from the Phase 2 study of CM24, in combination with Bristol Myers Squibb’s immune checkpoint inhibitor nivolumab and standard of care chemotherapy, in second-line metastatic pancreatic ductal adenocarcinoma. The event will also focus on data reported at the 2024 ASCO Annual Meeting demonstrating reduced risk of death and progression, prolongation of OS and progression free survival, higher objective response rate, disease control rate and decreasing CA19-9 levels in the CM24+Nivolumab+Nal-IRI/5FU/LV arm and the new exploratory biomarker data suggesting that baseline serum myeloperoxidase may be a predictive biomarker for the treatment effect of CM24-nivolumab therapy on overall survival. CM24 is a humanized monoclonal antibody that blocks the interactions of CEACAM1, a protein expressed on tumor and immune cells, and is a part of the Neutrophils Extra Cellular Traps, involved in tumor immune evasion and survival through multiple pathways.